BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

ESBATech AG 

Winterthurerstr. 190

Zurich    CH-8057  Switzerland
Phone: 41-1-635-3159 Fax: +41-1-635 2001


SEARCH JOBS




Industry
Biotechnology






 Company News
OctoPlus Expands Development Agreement With ESBATech on Controlled Release Product for Ophthalmic Indications 2/24/2011 8:19:03 AM
Alcon Laboratories, Inc. (ACL) to Acquire Swiss Biotechnology Firm, ESBATech for $589 Million 9/14/2009 7:05:15 AM
ESBATech: Topical ESBA105 Demonstrates Efficacy in the Back of the Eye to Inhibit Neovascularization 3/24/2009 10:57:57 AM
ESBATech's Antibody Fragment ESBA105 Enters Phase IIa in Uveitis Study 2/24/2009 10:48:39 AM
ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology 2/3/2009 10:42:52 AM
ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 1/9/2009 7:59:57 AM
ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications Preclinical Pharmacokinetic Data to be Presented at the 7th International Symposium on Uveitis in Germany 9/8/2008 9:47:13 AM
ESBATech Raises Additional $22M, Extending Series B Venture Financing Positive Results to Date Drive Decision to Expand its Proprietary Therapeutic Pipeline 8/7/2008 6:36:18 AM
ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications 4/24/2008 7:40:21 AM
ESBATech's Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops 2/25/2008 8:10:59 AM
12